Neonc Technologies Holdings, Inc. (NTHI) · Nov 3, 2026 · Other events
No new info
NeOnc’s SNO announcement sets two NEO100 and NEO212 data presentations, but the 8-K contains no new clinical results.
NeOnc is a clinical-stage CNS biotech advancing intranasal NEO100 through Phase 2 work and oral NEO212 toward Phase 2 development. This filing is a catalyst notice, not a clinical readout. It says data from both programs will be presented at the Society for Neuro-Oncology meeting on November 13, but provides no efficacy, safety, or statistical results. 〔0〕
The headline language is not the evidence. The NEO100 poster title references “durable radiographic remission and prolonged survival,” while the NEO212 title refers to “early signals of activity,” but those are presentation titles rather than disclosed results; the release itself reiterates that both programs remain investigational and that safety and efficacy have not been established. 〔1〕 〔2〕 The presentation schedule was already publicly announced on November 2, 2026, so the November 3 8-K mainly formalizes information the market already had.
Bottom line: This keeps an important clinical catalyst on the calendar but does not change the underlying business story today. The meaningful update arrives with the actual poster data on November 13, not with this filing itself.
SNO poster presentations, November 13, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!